JP7696900B2 - Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 - Google Patents

Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 Download PDF

Info

Publication number
JP7696900B2
JP7696900B2 JP2022533411A JP2022533411A JP7696900B2 JP 7696900 B2 JP7696900 B2 JP 7696900B2 JP 2022533411 A JP2022533411 A JP 2022533411A JP 2022533411 A JP2022533411 A JP 2022533411A JP 7696900 B2 JP7696900 B2 JP 7696900B2
Authority
JP
Japan
Prior art keywords
copd
subject
antibody
fev1
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022533411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505215A5 (enExample
JP2023505215A (ja
Inventor
ラオラット・アブデュライ
アレクサンダー・ボディ
シャオドン・ロウ
デボラ・デュコヴィッチ
アンドレアス・ジェッセル
ヘリベルト・シュタウディンガー
アリエール・テパー
エレーヌ・グラウイク
マルセラ・ルディ
ニキル・アミン
シヴァン・ハレル
チャド・ニヴェンズ
デーヴィッド・レデラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023505215A publication Critical patent/JP2023505215A/ja
Publication of JP2023505215A5 publication Critical patent/JP2023505215A5/ja
Priority to JP2025096567A priority Critical patent/JP2025164767A/ja
Application granted granted Critical
Publication of JP7696900B2 publication Critical patent/JP7696900B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022533411A 2019-12-06 2020-12-04 Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 Active JP7696900B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025096567A JP2025164767A (ja) 2019-12-06 2025-06-10 Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962944878P 2019-12-06 2019-12-06
US62/944,878 2019-12-06
US202062964966P 2020-01-23 2020-01-23
US62/964,966 2020-01-23
US202063082502P 2020-09-24 2020-09-24
US63/082,502 2020-09-24
PCT/US2020/063404 WO2021113707A1 (en) 2019-12-06 2020-12-04 Methods for treating copd by administering an il-33 antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025096567A Division JP2025164767A (ja) 2019-12-06 2025-06-10 Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法

Publications (3)

Publication Number Publication Date
JP2023505215A JP2023505215A (ja) 2023-02-08
JP2023505215A5 JP2023505215A5 (enExample) 2023-12-08
JP7696900B2 true JP7696900B2 (ja) 2025-06-23

Family

ID=74104197

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533411A Active JP7696900B2 (ja) 2019-12-06 2020-12-04 Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
JP2025096567A Pending JP2025164767A (ja) 2019-12-06 2025-06-10 Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025096567A Pending JP2025164767A (ja) 2019-12-06 2025-06-10 Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法

Country Status (12)

Country Link
US (1) US20210230265A1 (enExample)
EP (1) EP4069365A1 (enExample)
JP (2) JP7696900B2 (enExample)
KR (1) KR20220110553A (enExample)
CN (1) CN114786775A (enExample)
AU (1) AU2020398168A1 (enExample)
BR (1) BR112022010934A2 (enExample)
CA (1) CA3160521A1 (enExample)
IL (1) IL293544A (enExample)
MX (1) MX2022006812A (enExample)
TW (1) TW202134273A (enExample)
WO (1) WO2021113707A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021258255A1 (en) * 2020-04-22 2022-10-27 The Board Of Regents Of The University Of Texas System Medication return platform for extracting value from unused medications
TW202540173A (zh) * 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102597A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102597A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Also Published As

Publication number Publication date
CA3160521A1 (en) 2021-06-10
CN114786775A (zh) 2022-07-22
WO2021113707A1 (en) 2021-06-10
EP4069365A1 (en) 2022-10-12
BR112022010934A2 (pt) 2022-11-29
JP2025164767A (ja) 2025-10-30
MX2022006812A (es) 2022-08-25
IL293544A (en) 2022-08-01
JP2023505215A (ja) 2023-02-08
KR20220110553A (ko) 2022-08-08
AU2020398168A1 (en) 2022-07-28
US20210230265A1 (en) 2021-07-29
TW202134273A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
US20260055198A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
JP7315545B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
EP3973987B1 (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
AU2020266593B2 (en) Methods for treating or preventing asthma by administering an IL-33 antagonist
JP2025164767A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
JP2026068738A (ja) Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
US20240360232A1 (en) Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
RU2838119C2 (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-33
EA052377B1 (ru) Применение антитела, которое специфически связывает il-33, для лечения copd
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
EA050548B1 (ru) Способы лечения или предупреждения аллергической астмы посредством введения антагониста il-33 и/или антагониста il-4r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250611

R150 Certificate of patent or registration of utility model

Ref document number: 7696900

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150